Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on November 9, 2017, reporting an event that occurred on November 7, 2017. The filing addresses a material definitive agreement entered into with Aegis Capital Corp.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the specific transaction described below:
- Cash payment: $100,000
- Equity issuance: 60,000 shares of restricted common stock
Material Changes
The Company entered into a Release Agreement with Aegis Capital Corp. to terminate the "Right of First Refusal" previously granted to Aegis under an underwriting agreement dated August 3, 2017. This right had obligated the Company to offer Aegis the opportunity to underwrite all public and private equity and debt offerings for twelve months following a prior public offering. The Release fully discharges the Company from these obligations.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general risks. The transaction is presented as a settlement to remove a contractual restriction on future capital raising activities. The full text of the Release is incorporated by reference in the Company's upcoming Form 10-K for the fiscal year ended September 30, 2017.
Key Facts for Investor Verification
- Verify the impact of the 60,000 share issuance on total outstanding shares and potential dilution.
- Confirm the cash outflow of $100,000 against the Company's current liquidity position.
- Review the full text of the Release Agreement in the subsequent Form 10-K filing for any additional covenants or conditions.
- Assess the strategic rationale for terminating the underwriting relationship with Aegis Capital Corp.